iShares U.S. Pharmaceuticals ETF $IHE Stock Position Reduced by Royal Bank of Canada

Royal Bank of Canada lessened its stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 25.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 116,293 shares of the company’s stock after selling 40,680 shares during the quarter. Royal Bank of Canada’s holdings in iShares U.S. Pharmaceuticals ETF were worth $10,080,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IHE. Foundations Investment Advisors LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the 4th quarter valued at $54,513,000. BNP Paribas Financial Markets purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the second quarter worth $13,108,000. Anfield Capital Management LLC purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $10,007,000. JPMorgan Chase & Co. boosted its position in iShares U.S. Pharmaceuticals ETF by 89.4% during the fourth quarter. JPMorgan Chase & Co. now owns 212,805 shares of the company’s stock valued at $18,052,000 after purchasing an additional 100,426 shares during the last quarter. Finally, Cetera Investment Advisers boosted its position in iShares U.S. Pharmaceuticals ETF by 675.4% during the first quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock valued at $9,489,000 after purchasing an additional 95,353 shares during the last quarter.

iShares U.S. Pharmaceuticals ETF Price Performance

Shares of NYSEARCA IHE opened at $102.47 on Monday. iShares U.S. Pharmaceuticals ETF has a one year low of $65.60 and a one year high of $105.02. The business’s 50-day moving average price is $98.00 and its two-hundred day moving average price is $91.60. The company has a market capitalization of $1.64 billion, a P/E ratio of 17.75 and a beta of 0.48.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.